Brief: NanoViricides Has Requested A Pre-IND Meeting With The US FDA
26/03/2019 11:14
March 26 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES HAS REQUESTED A PRE-IND MEETING WITH THE US
FDA
* NANOVIRICIDES INC - SUBMITTED REQUEST FOR "TYPE B" PRE-IND
MEETING WITH US FDA FOR NV-HHV-101 DRUG CANDIDATE
* NANOVIRICIDES - BELIEVES RESULTING PRE-IND MEETING TO
PROVIDE
VALUABLE INFORMATION FOR DESIGNING CO'S CLINICAL PROGRAM FOR
NV-HHV-101 DRUG CANDIDATE
Source text for Eikon: ID:nPn3Pbf3ja
Further company coverage: NNVC.A
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments